http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0762934001&sourceType=1http://media3.marketwire.com/logos/20120124-ess200.jpg
WINDSOR, ONTARIO -- (Marketwire) -- 02/01/12 -- Essex Angel Capital Inc. (TSX VENTURE:EXC) (the "Corporation" or "Essex") is pleased to announce that Wellness Indicators, Inc. ("Wellness Indicators"), one of the companies in the Essex portfolio, has passed a significant milestone in producing the second generation of its proprietary electronic reader for its new wellness assessment test. The reader will be used in upcoming field trials for Wellness Indicators' Health Equater(TM) Assessment Profile, a unique inexpensive urine test that screens for a number of biomarkers. The company has field trial commitment letters from eight organizations, representing over 1,000,000 potential users, of whom 2,000 will be participating in field trials in the first quarter of 2012.
The reader for the Health Equater Assessment Profile is the culmination of research and development following field trials in July, 2011, and has been successfully bench-tested with more than 1,000 samples.
The Health Equater Assessment Profile is a first-to-market test screening for such biomarkers as oxidative stress, low-grade inflammation and total antioxidant capacity, which indicate levels of wellness. Thousands of studies have shown that the biomarkers detected by the assessment profile are leading indicators for a variety of future health risks, including stroke, cancer, heart disease, and diabetes. The value of the Health Equater Assessment Profile is that it is non-invasive, results are ready in five minutes and it gives an indication at the individual level of how a person is functioning metabolically before the onset of chronic disease, when intervention is less expensive and more effective. Results are available in approximately five minutes, instead of the week that traditional lab tests require. Other advantages include ease of use, portability, and low cost, being approximately $30 per test, rather than around $100 for most current diagnostic tests.
"We are confident that the Health Equater Assessment Profile is well on its way to a successful launch to the commercial market in the next few months," said Frank Lyman, President and CEO of Wellness Indicators.